Trade Panbela Therapeutics, Inc. - PBLA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.2 |
| Open | 1.2 |
| 1-Year Change | 34.83% |
| Day's Range | 1.07 - 1.24 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 6, 2024 | 1.08 | -0.12 | -10.00% | 1.20 | 1.25 | 1.06 |
| Mar 5, 2024 | 1.20 | 0.01 | 0.84% | 1.19 | 1.23 | 1.16 |
| Mar 4, 2024 | 1.18 | -0.06 | -4.84% | 1.24 | 1.27 | 1.16 |
| Mar 1, 2024 | 1.23 | 0.08 | 6.96% | 1.15 | 1.29 | 1.14 |
| Feb 29, 2024 | 1.14 | -0.06 | -5.00% | 1.20 | 1.22 | 1.12 |
| Feb 28, 2024 | 1.16 | -0.02 | -1.69% | 1.18 | 1.22 | 1.14 |
| Feb 27, 2024 | 1.21 | 0.08 | 7.08% | 1.13 | 1.21 | 1.13 |
| Feb 26, 2024 | 1.12 | 0.01 | 0.90% | 1.11 | 1.14 | 1.07 |
| Feb 23, 2024 | 1.09 | 0.00 | 0.00% | 1.09 | 1.11 | 1.07 |
| Feb 22, 2024 | 1.08 | -0.05 | -4.42% | 1.13 | 1.13 | 1.08 |
| Feb 21, 2024 | 1.11 | -0.05 | -4.31% | 1.16 | 1.16 | 1.11 |
| Feb 20, 2024 | 1.15 | -0.05 | -4.17% | 1.20 | 1.20 | 1.13 |
| Feb 16, 2024 | 1.22 | -0.01 | -0.81% | 1.23 | 1.29 | 1.21 |
| Feb 15, 2024 | 1.25 | -0.11 | -8.09% | 1.36 | 1.38 | 1.19 |
| Feb 14, 2024 | 1.31 | 0.21 | 19.09% | 1.10 | 1.46 | 1.10 |
| Feb 13, 2024 | 1.11 | -0.02 | -1.77% | 1.13 | 1.13 | 1.09 |
| Feb 12, 2024 | 1.16 | -0.05 | -4.13% | 1.21 | 1.21 | 1.12 |
| Feb 9, 2024 | 1.20 | 0.10 | 9.09% | 1.10 | 1.22 | 1.08 |
| Feb 8, 2024 | 1.12 | -0.02 | -1.75% | 1.14 | 1.14 | 1.05 |
| Feb 7, 2024 | 1.14 | 0.00 | 0.00% | 1.14 | 1.17 | 1.08 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Panbela Therapeutics, Inc. Company profile
About Panbela Therapeutics Inc
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing disruptive therapeutics for the treatment of patients with cancer. The Company is engaged in the commercial development of a polyamine analogue for pancreatic cancer. Its product candidate includes SBP-101, which is a proprietary polyamine analogue that accumulates in the exocrine pancreas acinar cells due to its chemical structure. The Company is conducting Phase I a/I b study of the safety, efficacy and pharmacokinetics of SBP-101 administered in combination with two standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Panbela Therapeutics Inc revenues was not reported. Net loss increased 70% to $6.6M. Higher net loss reflects Research and Development - Balancing increase of 90% to $3.2M (expense), General and administrative -Bal increase of 69% to $2.5M (expense), Other income decrease from $55K (income) to $611K (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
712 Vista Blvd # 305
55387
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com